We are live on ! Find out more
VA

VR Adviser Portfolio holdings

AUM $2.68B
1-Year Est. Return 422.73%
This Fund
S&P 500
This Quarter Est. Return
+25.77%
1 Year Est. Return
+422.73%
3 Year Est. Return
+1,447.09%
5 Year Est. Return
+3,249.52%
10 Year Est. Return
–
AUM
$1.91B
AUM Growth
+$339M
Cap. Flow
+$72.2M
Cap. Flow %
3.78%
Top 10 Hldgs %
65.6%
Holding
38
New
3
Increased
6
Reduced
6
Closed
–

Top Buys

Rank Stock Value
1
ORKA
Oruka Therapeutics
ORKA
+$105M
2
ARTV
Artiva Biotherapeutics
ARTV
+$18.7M
3
CASI
CASI Pharmaceuticals
CASI
+$5.66M
4
ENGN icon
enGene Therapeutics
ENGN
+$5.5M
5
APLT
Applied Therapeutics
APLT
+$1.66M

Top Sells

Rank Stock Value
1
MRUS
Merus
MRUS
+$18.5M
2
EWTX icon
Edgewise Therapeutics
EWTX
+$16.3M
3
ZURA icon
Zura Bio
ZURA
+$14.9M
4
DNTH icon
Dianthus Therapeutics
DNTH
+$9.75M
5
ARVN icon
Arvinas
ARVN
+$4.53M

Sector Composition

Rank Sector Weight
1 Healthcare 99.61%
2 Financials 0.39%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
APGE icon
1
Apogee Therapeutics
APGE
$10.1B
$499M 26.13%
8,493,321
– –
OCUL icon
2
Ocular Therapeutix
OCUL
$1.79B
$111M 5.82%
12,762,462
– –
ELVN icon
3
Enliven Therapeutics
ELVN
$3.92B
$103M 5.39%
4,026,331
– –
VRDN icon
4
Viridian Therapeutics
VRDN
$2.09B
$88.3M 4.63%
3,882,709
+38
+0% +$621
APLT
5
DELISTED
Applied Therapeutics
APLT
$83.5M 4.37%
9,825,000
+282,129
+3% +$1.66M
SYRE icon
6
Spyre Therapeutics
SYRE
$8.54B
$79M 4.14%
2,685,448
– –
DYN icon
7
Dyne Therapeutics
DYN
$4.7B
$78.1M 4.09%
2,173,913
– –
ORKA
8
Oruka Therapeutics
ORKA
$5.82B
$75.6M 3.96%
3,085,620
+3,013,422
+4,174% +$105M
KALV
9
DELISTED
KalVista Pharmaceuticals
KALV
$72.4M 3.79%
6,249,731
– –
PHVS icon
10
Pharvaris
PHVS
$2.28B
$62.9M 3.29%
3,395,606
– –
COGT icon
11
Cogent Biosciences
COGT
$6.65B
$61.4M 3.22%
5,684,167
– –
DNTH icon
12
Dianthus Therapeutics
DNTH
$5.84B
$47.8M 2.5%
1,744,373
-350,000
-17% -$9.75M
FDMT icon
13
4D Molecular Therapeutics
FDMT
$532M
$47.6M 2.49%
4,400,000
– –
MRUS
14
DELISTED
Merus
MRUS
$45.4M 2.38%
907,963
-355,251
-28% -$18.5M
ORIC icon
15
Oric Pharmaceuticals
ORIC
$1.15B
$45M 2.36%
4,394,527
– –
ERAS icon
16
Erasca
ERAS
$6.3B
$44.3M 2.32%
16,216,216
– –
PRAX icon
17
Praxis Precision Medicines
PRAX
$8.58B
$40.6M 2.13%
706,131
– –
ATXS
18
DELISTED
Astria Therapeutics
ATXS
$38.1M 1.99%
3,458,645
-150,000
-4% -$1.67M
TERN
19
DELISTED
Terns Pharmaceuticals
TERN
$28.4M 1.49%
3,410,058
– –
AQST icon
20
Aquestive Therapeutics
AQST
$463M
$27.7M 1.45%
5,555,555
– –
EWTX icon
21
Edgewise Therapeutics
EWTX
$4.13B
$26.7M 1.4%
1,000,000
-818,182
-45% -$16.3M
ARTV
22
Artiva Biotherapeutics
ARTV
$491M
$24.9M 1.3%
+1,609,569
New +$18.7M
ENGN icon
23
enGene Therapeutics
ENGN
$120M
$23.5M 1.23%
3,565,841
+739,858
+26% +$5.5M
CGEM icon
24
Cullinan Oncology
CGEM
$1.01B
$23.1M 1.21%
1,379,965
– –
MRSN
25
DELISTED
Mersana Therapeutics
MRSN
$21.4M 1.12%
453,120
– –
1
2

Similar funds

MMEA
Main Management ETF Advisors San Francisco, California $2.68B AUM 24.27% 1-Year Est. Return
WGI
Westwood Global Investments Boston, Massachusetts $2.68B AUM 76.4% 1-Year Est. Return
TCAM
Turtle Creek Asset Management Toronto, Ontario, Canada $2.67B AUM 0.64% 1-Year Est. Return
SFI
Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $2.67B AUM 21.74% 1-Year Est. Return
HC
Henshaw Capital Woburn, Massachusetts $2.7B AUM 29.67% 1-Year Est. Return
CI
Capital International Los Angeles, California $2.7B AUM 31.08% 1-Year Est. Return
PCA
Pallas Capital Advisors Braintree, Massachusetts $2.66B AUM 22.31% 1-Year Est. Return
LP
Longaeva Partners Chicago, Illinois $2.7B AUM 37.16% 1-Year Est. Return

VR Adviser's Q3 2024 Portfolio in Review

As of Q3 2024, VR Adviser held 38 positions worth $1.91B, up 22% from $1.57B the previous quarter. Its ten largest holdings account for 66% of the portfolio.

VR Adviser deployed $72.2M of net new capital in Q3 2024, opening 3 new positions and adding to 6 existing holdings. Its largest new stake was Artiva Biotherapeutics: 1,609,569 shares worth $24.9M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Merus, an estimated $18.5M trimmed.

  • VR Adviser's largest Q3 2024 buy was Artiva Biotherapeutics: 1,609,569 shares worth $24.9M.
  • VR Adviser added most to Oruka Therapeutics in Q3 2024, an estimated $105M increase.
  • VR Adviser's biggest Q3 2024 reduction was Merus, cutting an estimated $18.5M.
  • VR Adviser's ten largest holdings make up 66% of its $1.91B portfolio in Q3 2024.
  • VR Adviser opened 3 new positions and closed 0 in Q3 2024.
  • VR Adviser's portfolio value rose 22% quarter-over-quarter to $1.91B.

Based on VR Adviser's 13F filing for Q3 2024, filed 14 Nov 2024.